SEHK:3696Life Sciences
InSilico Medicine (SEHK:3696) Advances Rentosertib Into Phase 3 Trials
InSilico Medicine Cayman TopCo (SEHK:3696) reported that its AI-discovered drug rentosertib has progressed into Phase 3 clinical trials.
New peer-reviewed studies on rentosertib indicate reversal of biological age in treated patients, based on multiple independent aging models.
Global research collaborators are using rentosertib trials to build frameworks that embed aging biomarkers into idiopathic pulmonary fibrosis studies.
The move of rentosertib into Phase 3, together with the reported...